10-Q: 3D Systems Q3 2025: Revenue Declines Amid Divestitures

3D Systems Corporation reported a significant revenue decline in Q3 2025, driven by lower product sales and the impact of recent divestitures, despite improved net income for the nine-month period due to a large gain on disposition.

Summary

• Total revenue for the three months ended September 30, 2025, decreased by 19.2% to $91.2 million, down from $112.9 million in the prior year period.
• Total revenue for the nine months ended September 30, 2025, decreased by 14.7% to $280.6 million, down from $329.1 million in the prior year period.
• Net loss attributable to 3D Systems Corporation for Q3 2025 was $18.1 million ($0.14 per share), a significant improvement from a net loss of $178.6 million ($1.35 per share) in Q3 2024.
• Net income attributable to 3D Systems Corporation for the nine months ended September 30, 2025, was $49.4 million ($0.38 basic, $0.29 diluted per share), compared to a net loss of $221.9 million ($1.69 per share) in the prior year period.
• The nine-month net income was largely driven by a $125.7 million pre-tax gain from the sale of the Geomagic software business.
• Gross profit margin decreased to 32.3% in Q3 2025 from 36.9% in Q3 2024, and to 35.0% for the nine months ended September 30, 2025, from 39.4% in the prior year period.
• Operating expenses decreased significantly, with Selling, General and Administrative (SG&A) expenses down $23.3 million (40.1%) in Q3 2025 and Research and Development (R&D) expenses down $4.7 million (22.8%).
• Cash and cash equivalents decreased by $75.8 million since December 31, 2024, to $95.5 million.
• The company completed the sale of its 3DXpert and Oqton businesses in October 2025 for $3.5 million plus a potential revenue-based royalty of up to $12.9 million.
• A 2025 Restructuring Plan is underway, expected to incur $8.5 million to $14.5 million in pre-tax charges, primarily for employee severance.
• The company repurchased 8.0 million shares of common stock for $15.0 million in June 2025.
• Issued $92.0 million in 5.875% convertible senior secured notes due 2030 and used proceeds plus $78.0 million cash to repurchase $179.7 million of 0% convertible senior notes due 2026, resulting in an $8.2 million gain on debt extinguishment.

Sentiment

Score: 4

Explanation: The company experienced significant revenue and gross profit declines, coupled with increased cash usage from operations. While net income for the nine-month period was positive due to a large one-time gain from divestiture, underlying operational performance remains challenged by macroeconomic factors and specific market softness. Cost-cutting measures and debt refinancing are underway, but the core business faces headwinds, and multiple legal proceedings add uncertainty.

Positives

• Net income for the nine months ended September 30, 2025, significantly improved to $49.4 million, compared to a $221.9 million loss in the prior year, primarily due to a $125.7 million gain on the Geomagic divestiture.
• Operating expenses saw substantial reductions, with SG&A decreasing by $23.3 million (40.1%) in Q3 2025 and $48.1 million (28.9%) for the nine months, and R&D decreasing by $4.7 million (22.8%) in Q3 2025 and $13.2 million (19.9%) for the nine months.
• Successfully refinanced debt by issuing $92.0 million in 2030 Notes and repurchasing $179.7 million of 2026 Notes, leading to an $8.2 million gain on debt extinguishment.
• Repurchased 8.0 million shares of common stock for $15.0 million, a move structured to mitigate potential dilution from the new convertible notes.
• No goodwill impairment was identified in the interim assessment for the Healthcare reporting unit in Q2 2025, contrasting with a $101.4 million impairment in the prior year.
• Foreign exchange gain, net, increased by $4.6 million in Q3 2025 and $2.9 million for the nine months, primarily due to realized and unrealized gains from foreign operations.

Negatives

• Total revenue decreased by 19.2% in Q3 2025 ($21.7 million decline) and 14.7% for the nine months ($48.5 million decline) compared to prior year periods, driven by lower product sales and divestitures.
• Product revenue declined significantly due to lower materials volume to customers in the dental, service bureaus, and jewelry markets, and the impact of the Geomagic divestiture.
• Gross profit decreased by $12.3 million (29.4%) in Q3 2025 and $31.5 million (24.3%) for the nine months, with gross profit margin falling to 32.3% from 36.9% in Q3 2024 and to 35.0% from 39.4% for the nine months.
• Net cash used in operating activities increased significantly to $73.1 million for the nine months ended September 30, 2025, from $37.1 million in the prior year.
• Cash and cash equivalents decreased by $75.8 million since December 31, 2024, to $95.5 million.
• Interest expense increased by $1.3 million for both the three and nine months ended September 30, 2025, primarily due to the new 2030 Notes.
• One customer accounted for 11.2% and 10.9% of consolidated revenue for the three and nine months ended September 30, 2025, respectively, indicating customer concentration risk.
• Ongoing macroeconomic challenges continue to impact financial performance and cash flows.

Risks

• Impact on business from macroeconomic events and geopolitical risks, recession, supply chain disruptions, inflation, interest rates, and foreign exchange volatility.
• Ability to deliver products that meet changing technology and customer needs.
• Ability to identify strategic acquisitions, integrate them without disruption, and realize anticipated benefits, as well as realize anticipated benefits for future dispositions.
• Potential for future write-offs or write-downs of goodwill and intangible assets.
• Concentration of revenue and credit risk exposure from the largest customer.
• Ability to acquire and enforce intellectual property rights and defend against third-party claims.
• Failure of information technology infrastructure or inability to protect against cyber-attacks.
• Ability to predict quarterly sales and manage product inventory due to uneven sales cycles.
• Ability to generate net cash flow from operations.
• Ability to service debt and raise funds necessary to settle conversions of the 2030 Notes or 2026 Notes in cash, repay them at maturity, or repurchase them upon put rights or fundamental changes.
• Ability to comply with covenants in the 2030 and 2026 Indentures and other debt agreements, including financial covenants and restrictions on incurring additional debt, making investments, and restricted payments.
• Ability to remediate material weaknesses in internal controls over financial reporting and maintain effective internal controls.
• Fluctuations in gross profit margins, operating income or loss, and/or net income or loss.
• Ability to efficiently conduct business outside the U.S.
• Dependence on the supply chain for components, sub-assemblies, and raw materials.
• Ability to manage the costs and effects of litigation, investigations, or similar matters.
• Product quality problems that result in decreased sales and operating margin, product returns, product liability, warranty, or other claims.
• Ability to retain key employees and attract and retain new qualified employees while controlling labor costs.
• Ability to successfully develop and commercialize regenerative medicine products.
• Disruption in management information systems for inventory management, distribution, and other key functions.
• Compliance with U.S. and other anti-corruption laws, data privacy laws, trade controls, economic sanctions, and similar laws and regulations.
• Ability to maintain status as a responsible contractor under federal rules and regulations.
• Changes in, or interpretation of, tax rules and regulations.
• Inability to use a Form S-3 Registration Statement.

Future Outlook

The 2025 Restructuring Plan is expected to continue to deliver cost savings and improve cash flows in the second half of fiscal 2025. The company anticipates incurring approximately $8.5 million to $14.5 million in pre-tax restructuring charges, primarily for employee severance, through the second fiscal quarter of 2026. Management believes that current cash, cash equivalents, and other potential liquidity sources, such as issuing equity or debt securities, will be sufficient to meet anticipated cash requirements for the next twelve months. However, future changes in operating results, cash flows, share price, market capitalization, or discount rates could adversely affect goodwill's implied fair value, potentially leading to future impairment charges.

Management Comments

• Management believes that the disclosures included in this Form 10-Q are adequate to make the information presented not misleading.
• In management's opinion, the unaudited condensed consolidated financial statements contain all adjustments, consisting of adjustments of a normal recurring nature, necessary to present fairly the Company's financial position, results of operations, and cash flows for the periods presented.
• Although expectations reflected in forward-looking statements are believed to be reasonable, they are not, and should not be relied upon as a guarantee of future performance or results.
• While challenging macroeconomic conditions have impacted financial performance and cash flows, cash, cash equivalents, and other sources of liquidity are expected to be available and sufficient to meet anticipated cash requirements.

Industry Context

The company operates within the 3D printing and digital manufacturing solutions industry, serving Healthcare Solutions (dental, medical devices, personalized health services, regenerative medicine) and Industrial Solutions (aerospace, defense, transportation, general manufacturing). The filing indicates that 'continuing macroeconomic challenges' and 'continued uncertainty in the economy and our industry' are impacting financial performance. Specific market softness is noted in lower materials volume to customers in the dental, service bureaus, and jewelry markets. Conversely, increased sales in the aerospace and defense market for Industrial Solutions suggest some areas of resilience or growth within the broader industry.

Comparison to Industry Standards

• The filing does not provide specific comparisons to global benchmarks, comparable companies, projects, or results within the industry.

Management Changes

Corporate Governance

Legal Proceedings

• SEC Investigation: Formal investigation initiated April 15, 2022, related to allegations in a securities class action lawsuit, with subpoenas received and company cooperation ongoing.
• Volumetric Milestones Dispute: Company terminated four earnout milestones due to loss of funding, reducing maximum liability from $355.0 million to $175.0 million. Key employees resigned, making remaining earnouts ineligible. Former owners initiated dispute resolution, and the Company proposed a $1.8 million settlement, which has not been accepted. A Notice of Claim for Indemnification was received, to which the Company served a Notice of Objection denying liability.
• Intrepid Automation Lawsuits: 3D Systems initiated a 2021 lawsuit alleging theft of trade secrets, unfair competition, and breach of contract, but the court dismissed the Company's claims in March 2025. Intrepid Automation filed counterclaims seeking over $20 million, which are ongoing. Intrepid Automation also filed a 2024 lawsuit alleging patent infringement, seeking unspecified damages and injunctive relief, with 3D Systems filing IPR petitions and a motion to stay.
• Securities Class Action: Filed June 13, 2025, alleging violations of the Securities Exchange Act of 1934 and SEC Rule 10b-5 by making false and misleading statements and omissions, seeking monetary damages for stockholders who purchased common stock between August 13, 2024, and May 12, 2025.
• Derivative Actions: Multiple lawsuits filed in U.S. District Courts and South Carolina Court of Common Pleas against officers and directors (and the Company as nominal defendant) alleging violations of Section 14(a) of the Exchange Act, breach of fiduciary duties, unjust enrichment, gross mismanagement, and waste of corporate assets. Several actions have been consolidated.
• Government Settlement: Settled export control violations in February 2023, agreeing to pay $15.0 million in civil monetary penalties and a $10.0 million suspended penalty for remedial compliance. The final $3.0 million installment was paid in Q1 2025, with $5.1 million of the suspended penalty balance remaining.

Related Party Transactions

• Note Receivable Related Party: The Company extended a short-term, non-interest bearing loan to NAMI Joint Venture (a joint venture with Saudi Arabian Industrial Investments Company) for $2.0 million in December 2024. The loan's maturity was extended to June 30, 2026, and the total related party note receivable increased to $4.4 million as of September 30, 2025.
• Other Asset: In February 2025, the Company provided $1.0 million in financing to Hull Legacy Media Corporation, a production company co-owned by Charles W. Hull, EVP, Chief Technology Officer for the Company's Regenerative Medicine business and a related party.

Stakeholder Impact

• Shareholders: Face potential dilution from convertible notes (though mitigated by share repurchase), impact of declining revenue and gross profit on stock performance, uncertainty from multiple legal proceedings (securities class action, derivative actions), and potential for future goodwill impairment. Benefited from a $125.7 million gain on disposition and an $8.2 million gain on debt extinguishment.
• Employees: Affected by the 2025 Restructuring Plan, including labor force reductions and severance costs. Stock-based compensation expense reversal due to forfeiture of PSUs and cancellation of 2025 annual incentive compensation. Resignation of key Volumetric employees impacted earnout potential.
• Customers: May experience changes in product/service offerings and support due to divestitures of Geomagic, 3DXpert, and Oqton. Lower materials volume in dental, service bureaus, and jewelry markets indicates reduced demand or competitive pressure.
• Creditors/Noteholders: The new 5.875% convertible senior secured notes due 2030 are senior secured obligations, offering some protection. Compliance with financial covenants in indentures is critical. Holders of 2030 Notes have a one-time put right on June 23, 2028.
• Suppliers: The company's dependence on its supply chain for components and raw materials continues, with purchase commitments totaling $17.4 million, of which $9.0 million is due within the next twelve months.

Next Steps

• Continue executing the 2025 Restructuring Plan to deliver cost savings and improve cash flows through the second fiscal quarter of 2026.
• Seek annual approval from the Directorate of Defense Trade Controls (DDTC) for the application of spend on remedial compliance measures as a reduction to the $10.0 million suspended penalty.
• Vigorously defend against the Intrepid Automation 2021 Lawsuit counterclaims and the 2024 patent infringement lawsuit.
• Vigorously defend against the Securities Class Action and multiple Derivative Actions.
• Evaluate the effects of recently issued accounting standards (ASU 2023-09, ASU 2024-03, ASU 2025-05, ASU 2025-06) on consolidated financial statements.
• Management may consider pursuing additional long-term financing if appropriate in light of cash requirements for operations or strategic opportunities.

Key Dates

Recommendation

While the company has taken steps to improve its financial structure through debt refinancing and cost-cutting, the core business performance shows significant weakness with declining revenue and gross profit margins. The positive net income for the nine-month period is largely due to a one-time asset sale, not sustained operational improvement. The company faces multiple ongoing legal challenges and has identified material weaknesses in its internal controls, adding considerable uncertainty. Given the mixed signals – strategic divestitures and cost reductions versus declining sales and legal risks – a "Hold" recommendation is appropriate. Investors should monitor the effectiveness of restructuring, resolution of legal issues, and signs of organic revenue growth before considering further investment.

Keywords

3D printing, Additive manufacturing, Healthcare solutions, Industrial solutions, SEC filing, 10-Q, Financial results, Revenue decline, Divestitures, Convertible notes, Restructuring, Goodwill impairment, Legal proceedings, Corporate governance, Financial performance